FDA Rx Compounding Ad Restrictions May Be Unnecessary, Justices Say
Executive Summary
FDA restrictions on advertising compounded drugs may not be justified given the additional safeguards provided under the FDA Modernization Act, U.S. Supreme Court justices suggested during oral arguments in Thompson v. Western States Medical Center Feb. 26
You may also be interested in...
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls
The Supreme Court decision overturning restrictions on advertising of compounded drugs suggests that any moves by Congress to control direct-to-consumer advertising will face a close, skeptical review in court
Supreme Court Reaffirms Least Restrictive Standard For Ad Controls
The Supreme Court decision overturning restrictions on advertising of compounded drugs suggests that any moves by Congress to control direct-to-consumer advertising will face a close, skeptical review in court
Pharmacy Compounding Could Be Added To PDUFA III, APhA’s Winckler Says
Pharmacy compounding could be revisited in the Prescription Drug User Fee Act if there is a Supreme Court decision before reauthorization is finalized, American Pharmaceutical Association Policy & Advocacy Group Director Susan Winckler said